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It is estimated that 54,000 new cases of Head and Neck Cancer will be diagnosed in the 
United States in 2021 (Cancer Facts and Figures, 2021).  Head and Neck cancers 
represent those that originate from sites which include the nasopharynx, oropharynx, oral 
cavity and hypo-pharynx.  In advanced cases, treatment modalities are combined to 
include surgery, radiation and chemotherapy.  Expected side effects of treatment can 
include mucositis, dysgeusia, dysphagia, odynophagia, nausea, vomiting and xerostomia.  
These toxicities can contribute to dehydration, weight loss and malnutrition.  This paper 
examines the current state of evidence as it pertains to nutritional outcomes for Head and 
Neck cancer patients receiving concurrent chemotherapy and radiation when prophylactic 
percutaneous endoscopic gastrostomy (PEG) tubes versus reactive tubes were used.  A 
retrospective chart review was conducted to examine the following research question:  
Does prophylactic percutaneous gastrostomy tube placement improve nutritional 
outcomes in patients receiving concurrent chemotherapy and radiation for Head and Neck 
Cancer patients when compared to those patients with reactive PEG tubes placed.  The 
results of this study identified that despite timing of tube placement, patients in both 
groups lost weight and showed signs of worsening nutritional outcomes as evidenced by 
decreased body mass index, total protein, and albumin levels.  Advanced practice nurses 
are in a unique position to develop innovative approaches to enhance nutrition in this 
patient population.  Risk assessment tools, interdisciplinary collaboration and the 
development of a Head and Neck cancer pre-habilitation clinic may improve nutritional 
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Prophylactic Percutaneous Endoscopic Gastric Tubes for Head and Neck Cancer:  Are 
They Worth Their Weight? 
 
Background/Statement of the Problem 
Head and Neck cancer refers to malignancies that include the lip, oral cavity, 
pharynx, larynx and para nasal sinuses.  In the United States, it is estimated that over 
54,000 new cases of Head and Neck cancer will be diagnosed in 2021 (Cancer Facts and 
Figures, 2021) and greater than ninety percent of these patients are determined to have 
squamous cell pathology.  Tobacco and alcohol have been identified as the most common 
causative agents which contribute to the development of this complex disease. Patients 
with Head and Neck cancer are also at an increased risk for secondary primary cancers of 
the Head and Neck as well as cancers of the aero digestive tract. 
Treatment modalities for these cancers include surgery, chemotherapy, 
immunotherapy and radiation alone or in combination.  Treatment is complicated and 
guided by site of disease, stage and pathological findings.  A multitude of physical and 
functional impairments result from treatment related toxicities, disease itself and health 
behaviors.  Nutritional complications are often present before treatment is initiated if the 
tumor is present in the oral cavity or throat (Lees, 1999).  Pain, xerostomia, mucositis, 
and impaired swallow function negatively affects the patient’s ability to maintain 
adequate nutrition and hydration.  Malnutrition has been associated with hospitalizations, 
treatment interruptions, decreased treatment efficacy and diminished quality of life. 
 Percutaneous endoscopic gastrostomy (PEG) tubes for enteral feeding  in patients 
with Head and Neck cancer, undergoing multimodal therapy, is often utilized to provide 
nutritional support in this at-risk population (Kasozi et al., 2018).  Percutaneous 
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endoscopic gastric (PEG) tubes may be placed prophylactically in anticipation of patient 
needs prior to beginning treatment or reactively, during or after treatment, when the 
patient can no longer meet their nutritional requirements.  Prophylactic PEG tube 
placement is a common practice despite the lack of research to support the procedure.  
Although PEG tube placement timing is discussed frequently in the literature, there is no 
consensus on whether prophylactic versus reactive placement for Head and Neck cancer 
patients is preferable (Locher et al., 2011).     
The National Comprehensive Cancer Network (NCCN) does not recommend the 
placement of prophylactic PEG tubes in patients with very good performance status or for 
patients without significant pre-treatment weight loss, significant airway obstruction or 
severe dysphagia.  However, the NCCN guidelines state that PEG tubes should be 
strongly considered if patients have severe weight loss prior to treatment.  Percutaneous 
endoscopic gastric tubes should also be considered if patients experience ongoing 
dehydration, dysphagia, anorexia or pain which prohibits the ability to eat or drink.  
Aspiration risk, comorbidities, radiation field and impaired swallow function are other 
factors that influence prophylactic tube placement in the Head and Neck cancer patient.  
 The purpose of the Cochrane Systematic Review was to compare the 
effectiveness of different enteral feeding methods (PEG vs. nasogastric) used in the 
nutritional management of patients with Head and Neck cancer receiving radiotherapy or 
chemo radiotherapy using clinical outcomes, nutritional status, quality of life and rates of 
complications (Nugent et al., 2011).  There was insufficient evidence to make a 
determination on the optimal method of enteral feeding.  Timing of tube placements were 
not studied.  Although PEG tube placement is considered relatively safe, complications 
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can occur.  Infection, tube obstruction, migration and dislodgement are common 
occurrences.  More serious complications such as peritonitis, abscess or fistula 
development are rare (Riera, 2002).  Long term negative outcomes with PEG tube 
placements include tube dependency, loss of swallow function, and metastasis or seeding 
at the PEG tube site.  Furthermore, some prophylactic PEG tubes placed may never be 
used.   It is important to assess each patient and weigh the risks and benefits of 
prophylactic versus reactive tube placement while considering the potential effects on 
quality of life.  Because the decision to place a PEG tube often relies on patient values 
and clinician preferences, additional research is needed to understand the use of 
prophylactic feeding tube placement in this compromised patient population and provide 
evidence based guidelines that can be followed by care teams.  The purpose of this study 
is to describe nutritional outcomes in the Head and Neck cancer population receiving 
concurrent chemotherapy/radiation in those patients with prophylactic endoscopic gastric 














A literature review was conducted using the Cumulative Index of Nursing and 
Allied Health Literature (CINAHL) and PUB MED databases.  Keywords used included 
combinations of head and neck cancer, neoplasm, prophylactic PEG tube, PEG, nutrition 
and malnutrition.  Literature was searched between 2011 and 2019.  Study indexes 
included English language and full-text.  Thirteen research articles retrieved and six were 
selected for literature review. 
Percutaneous Endoscopic Gastric Tube Placement  
 Most patients with Head and Neck cancer lose weight and are nutritionally 
compromised as a result of their disease, health behaviors and treatment-related toxicities 
making nutritional management important (NCCN, 2020).  Feedings through 
percutaneous endoscopic gastric (PEG) tubes, whether placed prophylactically or 
reactively, has become a relatively common practice in this population (Langius et al., 
2013).  Although PEG tube placement is considered relatively safe and has a low rate of 
significant associated complications, it brings both risks and benefits.  Currently, criteria 
for patient selection regarding PEG tube placements are not standardized and there are no 
published criteria or national guidelines on the optimum method of enteral tube feeding 
in this patient group (Nugent et al., 2010).  More research is needed to inform and guide 
provider decisions in regards to PEG tube placement and timing.    
A 2011 comprehensive review conducted by Locher et al., (2011) sought to 
describe the prevalence of PEG tube placement in patients undergoing treatment for Head 
and Neck cancer, describe factors associated with PEG tube placement at any time and to 
describe the reported and potential benefits and risks associated with PEG tube 
placement.  Seven hundred thirty-nine articles were identified for review and the authors 
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identified multiple benefits for prophylactic feeding tube placement.  Benefits included 
decreased weight loss, hospitalizations and treatment interruptions.  For example, one 
study included in this review was a prospective randomized trial by Salas et al., (2009).  
Researchers assigned Head and Neck cancer patients without nutritional deficits (prior to 
chemotherapy/radiation) to either receive prophylactic PEG tube or no PEG tube 
placement.  At six months, quality of life scores were higher in the prophylactic PEG 
placement arm.  Despite a small sample size, these findings suggest that further studies 
on PEG placement timing and quality of life may be of clinical interest.   
 Locher et al., (2011) identified that although there is no consensus in the literature 
to determine when PEG placement is preferable, it is an important and relevant clinical 
issue.  A gap in the literature exists as there is a lack of research looking into the use of 
prophylactic PEG tube placement and outcome evaluations in the Head and Neck cancer 
population.  In conclusion, more research is needed to guide physician practice when 
determining if prophylactic PEG tube placement in warranted in the treatment of Head 
and Neck cancer patients.   
 A retrospective chart review by Sachdev et al., (2015) conducted a detailed 
analysis of clinical and dosimetric parameters to better define factors that could predict 
requirements for enteral feeding.  Dosimetric parameters were defined as the mean dose, 
maximum dose and minimum dose of radiation to head and neck structures.  The 
investigators goal was to determine high risk patients with an objective to maximize 
targeted nutritional guidance, early supplementation, swallowing therapy and more 
aggressive symptomatic support.  The second aim was to determine if the research 
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derived in this study could support delays or prevent placement of a feeding tube thus 
preventing associated long term complications (Sachdev et al., 2015).   
 One hundred patients with locally advanced stage III and IV Head and Neck 
Squamous Cell Carcinoma were chronologically selected for study at Northwestern 
University Medical Center between 2005 and 2010.  Patients were excluded if their 
cancer stage was I or II, if a different treatment modality was administered and/or if a 
feeding tube was placed prior to treatment.  All patients were retrospectively analyzed 
after intensity-modulated radiation therapy was completed.  Ninety seven percent of 
patients received a combination of radiation and chemotherapy.  Patients were referred 
for a percutaneous endoscopic gastric tube if their weight loss exceeded ten percent due 
to reduced oral intake.  Univariate and multivariate analyses using logistic regression 
were used to determine clinical and dosimetric factors associated with needing enteral 
feeding (Sachdev et al., 2015).  Fischer’s exact tests and Wilcoxon rank-sum tests were 
also used for analysis.   
 Thirty-three percent of patients required placement of an enteral feeding tube.  
The median time to tube placement was twenty five days from start of treatment.  On 
univariate and multivariate analysis, age remained the only statistically significant factor 
(p=0.003) regardless of other clinical features and all radiation planning parameters 
(Sachdev et al., 2015).  In conclusion, age was found to be the most significant risk factor 
for needing a feeding tube in this patient population.  This research supported 
maximizing early nutritional guidance, targeted supplementation, and symptomatic 
support in patients older than sixty receiving concurrent chemotherapy and radiation.  
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Interventions may result in a delay or omission of enteral feeding theoretically reducing 
long term feeding tube complications such as tube dependence (Sachdev et al., 2015). 
Risks and Benefits of Percutaneous Endoscopic Gastric Tube Placement 
 Percutaneous endoscopic tubes can provide both risks and benefits in the Head 
and Neck cancer patients receiving concurrent chemotherapy/radiation.  Percutaneous 
endoscopic gastric tubes have been found to be effective in maintaining body weight and 
preventing malnutrition in this patient population.  Percutaneous endoscopic gastric tubes 
may decrease morbidity related to poor nutritional intake during cancer treatment and 
possibly prevent dehydration and unplanned hospitalizations (Bishop & Reed, 2015).  
Having a PEG in place may also improve treatment compliance and quality of life 
(Madhoun et. al., 2016).  Alternatively, infection, tube malfunction/migration are all 
common risks associated with tube placement.  Still, other data suggests even greater 
risks.  For example, enteral feeding can induce long term tube dependence and disuse of 
the swallowing mechanism which has been linked to complications such as prolonged 
dysphagia and esophageal constriction (Sachdev et. al., 2015).  Although infections and 
tube malfunction are more commonly seen adverse events associated with PEG tube 
placement, rare cases of seeding at the PEG site have also been reported (Cady, 2007).  
 Harm has been associated with prophylactic PEG tube placement.  Various 
complications such as infection, tube complications, alterations in elimination, sodium 
and glucose alterations, gastric bleeding, peritonitis, cellulitis, ileus, perforation, pain, 
gastric metastases and anesthesia risks were reported (Locher et al., 2011).  Furthermore, 
researchers have found that PEG dependence is a leading clinical predictor of quality of 
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life in this patient population.  Body image disturbance and loss of swallow function were 
also predicted to be a consequences of prophylactic PEG tube placement.   
  A systematic review completed by Orphanidou et al., (2011) studied prophylactic 
feeding tubes for patients with locally advanced Head and Neck cancer undergoing 
combined chemotherapy and radiotherapy.  The goals of this systematic review were to 
determine risks and benefits of prophylactic feeding tubes in the curative Head and Neck 
cancer population receiving combination chemotherapy/radiation and to make 
recommendations on the use of prophylactic feeding tubes and nutrition.   
          Studies were eligible for inclusion in the systematic review if they were published 
as full reports or publicly available abstracts in 1985 or later.  Participants in these 
eligible studies were adult patients with squamous cell carcinoma of the head and neck 
receiving combined chemotherapy/radiation with curative intent, either as primary 
therapy or after surgery, who had a PEG tube placed prior to treatment.  Twenty-one 
eligible studies were found.   None were randomized or quasi-randomized trials.  
Available studies were descriptive, four were prospective and 11 studies included a 
control group.  
 Orphanidau et al., (2011) reported available evidence as weak.  Therefore, the 
researchers could not conclude the effectiveness of prophylactic feeding tubes in the 
Head and Neck cancer population receiving concurrent chemotherapy and radiation in 
curative intended patients.  Insufficient quality and quantity of the evidence, difficulty 
with data analysis and patients lost to follow up were identified as study limitations.  
Furthermore, the body of evidence reviewed could not support an evidence-based clinical 
practice guideline, however, recommendations were made.   
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     Recommendations include using a comprehensive interdisciplinary approach in 
the care of the Head and Neck cancer patient before, during and after treatment 
commences (Orphanidau et al., 2011).  Investigators also point out that having a 
nutritional screening and referral process in place to identify patient at risk or 
experiencing malnutrition is essential.  Validated nutritional screenings tools are also 
necessary.  Assessment and interventions are meant to optimize nutrition and fluid intake, 
consider patients for tube placement, provide symptom management and preserve 
swallow function.  Rehab referral to speech and language pathology can focus on 
resumption of oral intake in an effort to prevent tube feed dependence.   
 The purpose of Alshadwi et al., (2013), literature review was to assess the current 
literature supporting the benefit of nutritional support, patient assessment and nutritional 
repletion, and the advantages and disadvantages of various alimentation modalities.  
Articles were reviewed that focused on the etiology and assessment of malnutrition and 
current nutritional treatments for cancer-induced anorexia and cachexia.  Two hundred 
forty-eight articles were found and a summative view was formulated.   
 Investigators concluded that nutritional interventions should be initiated before 
cancer treatment begins (Alshadwi et al., 2013).  Researchers summarized that 
gastrostomy tube placement before radiation therapy has been shown to prevent weight 
loss, treatment interruption, and dehydration (Alshadwi et al., 2013) and percutaneous 
endoscopic gastric tubes are preferred for patients who require tube feeds for more than 
thirty days.   
 One prospective multi-institution study of one hundred seventy two patients was 
reviewed.  It compared PEG tubes with gastric tubes.  According to this literature review, 
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gastric tubes had increased mortality rates and major complications.  However, PEG tube 
placements were noted to have cancer cell seeding at the insertion site and tumor 
implantation after endoscopic placement (Alshadwi et al., 2013).  Although reported as 
an incidence of up to one percent, it is worth noting.  In conclusion, researchers 
summarized that for high risk Head and Neck cancer patients who are unable to consume 
nutrition by mouth, enteral feeding must be provided.  
Dysphagia 
 Difficulty swallowing can be a presenting symptom in the Head and Neck cancer 
patient or a side effect of cancer treatment.  The tumor location itself can often cause 
nutritional complications before treatment begins, with 5–52% of patients reporting 
dysphagia before undergoing CRT or RT (Platteaux et al., 2010).   Dysphagia and 
swallow function can be measured by clinical swallow assessments or by video 
fluoroscopic swallow studies.  More common indicators or swallowing problems are 
weight loss, food intake or need for PEG tube intervention (Langmore et al., 2012).   
      A randomized controlled clinical trial by Silander et al., (2013) followed Head 
and Neck cancer patients for two years to measure their energy intake, choice of energy 
sources and to assess problems with dysphagia.  Energy intake in defined as oral, 
nutritional supplements, enteral and parenteral sources of nutrition.  The objective was to 
explore when and for how long the patients had dysphagia and lost weight due to 
insufficient intake, and if having a PEG tube in place made a difference.   
 The population was identified as patients with stages III or IV oral or pharyngeal 
cancer and included curative patients.  One hundred thirty-four patients were included 
and randomized to either a prophylactic PEG for early enteral feeding or nutritional care 
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according to clinical practice.  At seven time points, weight, dysphagia, and energy intake 
was measured (Silander et al., 2013).  Quality of life was measured using the European 
Organization for Research and Treatment of Cancer Quality of Life Questionnaire 
(EORTC-35) (Silander et al., 2013).   Food calculation software program AIVO Diet 32 
analyzed intake data.  Group comparisons were done using the Mann-Whitney U-test, 
Fisher’s Exact test and Mantel-Haenszel x2 for comparisons.  Statistical analysis was 
performed using SAS software.  Findings were reported using statistically significant data 
analysis.  
Both groups lost weight in the first six months due to insufficient energy intake 
and used enteral nutrition as their main intake source.  No significant differences between 
groups were found.  Neither of the groups reached their recommended protein 
requirements until six months after the start of treatment.  Although dysphagia was 
prevalent, after one year, dysphagia had decreased, and oral intake was the main energy 
source for both groups.  Study results concluded that a prophylactic PEG did not 
significantly improve enteral intake (Silander et al., 2013). 
Nutrition 
 Nutritional management is very important in head and neck cancer patients to 
improve outcomes and to minimize significant temporary or permanent treatment-related 
complications such as severe weight loss (NCCN, 2020).  All patients should be 
evaluated for nutritional risks and receive nutrition counseling by a registered dietician 
and have appropriate interventions made.  Percutaneous endoscopic gastric tubes may be 
recommended prior to or during treatment for patients at high risk for significant weight 
loss and malnutrition.    
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      Langmore et al., (2012) looked at whether PEG tube use caused dysphagia in 
Head and Neck Cancer patients undergoing radiotherapy.  The first aim was to determine 
whether patients who received a prophylactic PEG had better or worse swallowing 
function, diet scores, or weight change outcomes than patients who did not receive a 
prophylactic PEG tube.  The second aim of the study was to compare whether patients 
who used a feeding tube for all, some, or none of their nutrition, fared differently in terms 
of their swallow ability, diet level and weight change.  A retrospective chart review was 
conducted for all Head and Neck cancer patients treated with radiation at the Boston 
University Medical Center from January 2003 to September 2008.  Fifty nine patients 
met all inclusion and exclusion criteria.   
      Analyses were conducted to determine the impact of PEG use on long-term diet 
level and weight change (Langmore et al., 2012).  The investigators first evaluated 
whether patients who received prophylactic PEG had different outcomes (percentage of 
weight change and diet scores) than patients who did not receive a prophylactic PEG 
tube.  Second, researchers assessed whether diet level at the end of radiation for all 
patients were associated with percentage of weight change and diet scores (Langmore et 
al., 2012).  Data was collected at four capture points: the end of radiation and then again 
at 3, 6, and 12 months post placement.  For each analysis, linear mixed-effects models 
were used to evaluate relationships.  Kruskal-Wallis tests were used to analyze the 
association between diet status at baseline and diet scores at each time point.  For the diet 
level analysis, Tukey-Kramer method was used to identify significant pairwise 




      Results showed no statistically significant differences of weight loss between the 
two groups at each time period (Langmore et al., 2012).  In contrast to weight change 
results, the prophylactic PEG group had significantly worse diet outcomes than those 
who did not have prophylactic PEG tubes. However, those who did not receive 
prophylactic PEG’s and those who maintained an oral, or a partial oral diet during 
radiation, had significantly better diet outcomes at all touch points post radiation 
(Langmore et al., 2012).   
 A 2017 study of early prophylactic feeding versus standard care in patients with 
Head and Neck cancer was completed by Brown et al.  The purpose of the study was to 
evaluate the effectiveness of early prophylactic tube feeding compared to beginning tube 
feeding during treatment in patients undergoing prophylactic tube placement for patients 
with Head and Neck cancers.  One hundred and seventy four patients were invited to 
participate in the study between September 2012 to June 2015 with 131 patients recruited 
then randomized.  The primary outcome measure was the percentage of weight loss at 
three months post treatment (Brown et al., 2017).  This was a single-center randomized 
controlled trial conducted in Queensland, Australia. 
 In the standard care arm, patients were started on enteral nutrition via their 
prophylactic gastrostomy by the dietitian when oral intake was less than 60 percent of 
estimated nutritional requirements for greater than ten days, if the patient was losing 
weight, if the patient required diet modification of texture, or if the patient experienced 
and increase in symptoms which impacted their nutritional status.  The intervention group 
had enteral nutrition initiated via their prophylactic gastrostomy immediately following 
tube placement prior to the start of treatment. The prophylactic enteral nutrition was in 
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addition to their current oral intake and consisted of two 200ml bolus feedings daily 
(Brown et al., 2017).  Data was analyzed and found no significant differences for weight 
loss, body composition or nutritional status.  Researchers concluded that early 
intervention did not improve patient outcomes.   
P16 Tumor Suppressor Gene   
 An important gene product that is involved in Head and Neck squamous cell 
carcinoma (HNSCC) pathogenesis is the p16INK4a (p16) protein, made by 
the p16INK4a (CDKN2A) gene.  P16 is a cyclin-dependent kinase inhibitor that inhibits 
pRb phosphorylation and blocks cell cycle progression at the G1 to S check point (Lo et 
al., 1999).  Loss of p16 expression by deletion, mutation, or hypermethylation is common 
in HNSCC (Worsham et al., 2006) and is associated with a worse prognosis (Namazie et 
al., 2009).  P16 expression (p16 positive) has been correlated with improved outcomes in 
oral pharyngeal squamous cell carcinoma (Weinberger et al., 2004).  The biologic 
significance of HPV positivity includes improved prognosis for patients with HPV 
positive HNSCC relative to HPV negative HNSCC (Ang et al., 2010) due in part to a 
better therapeutic response to chemo/radiotherapy (Fakhry, et al., 2008).     
Verma et al., (2015) explored variables associated with poor prognosis in post-
operative p16 positive oropharyngeal squamous cell carcinoma patients receiving 
adjuvant radiotherapy or chemo-radiotherapy in relation to feeding tube insertion timing.  
Ninety-seven patients were eligible for this retrospective chart review which took place 
between 1997 and 2009.  Patients were grouped by those who had feeding tubes placed 
before radiation, patients who had feeding tubes placed during or after radiation, and 
patients who had no feeding tubes placed.  These groups were analyzed for differential 
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tumor, patient, treatment, feeding tube characteristics as well as overall survival, disease 
free survival, and distant metastasis free survival (Verma et al., 2015).    
      The study population was identified as oropharyngeal cancer patients who were 
p16 positive, post-operative and adjuvant radiation candidates (Verma et al., 2015).  After 
inclusion and exclusion criteria was met, ninety-seven patients were left for analysis.  
The primary endpoints were overall survival, disease free survival and distant metastases 
free survival.   Kruskal-Wallis, Fisher Exact tests, Kaplan-Meier curves, Cox 
proportional Hazard Models and a backward stepwise model selection approach were 
performed for statistical analysis.  
 Results showed that pre-radiation feeding tube insertions were associated with 
higher tumor size and depth, tumor (T) but not node (N), overall stage, comorbidities, 
presence of chemotherapy, and less use of trans-oral laser microsurgery (Verma et al., 
2015).  Time from surgery to intensity modulated radiation therapy completion was 
statistically longer in patients receiving prophylactic PEG tubes.  The feeding tubes were 
permanent in fifty-two percent of patient receiving prophylactic PEG tubes versus sixteen 
percent in the patient group who received PEG placement during or after treatment 
completion.  Five year overall survival rates were highest in patients without feeding 
tubes (90%) and lowest in patients with feeding tubes placed prophylactically (50%).  
Five year disease free survival (DFS) was highest in the patients without feeding tubes 
(87.6%) and lowest for patients who had prophylactic PEG tubes placed (42.7%).  
Multivariate analysis showed that for both overall survival and disease free survival, 
feeding tube placement time and smoking history were statistically significant (Verma et 
al., 2015).  This study concluded that early feeding tube insertion was correlated with a 
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poor prognosis.  The presence of a feeding tube at the time of radiation consult can be 
used as an alternate marker in the p16 positive oropharyngeal squamous cell carcinoma 
patients to identify worse disease status alerting clinicians that this patient population is 
in a higher risk sub group. 
PEG Tube Placement Timing  
For Head and Neck cancer patients undergoing treatment, there are two 
approaches to PEG tube feeding.  Percutaneous endoscopic gastric tubes may be placed 
prophylactically in anticipation of patient needs prior to treatment, or reactively during 
treatment at a time when the patient is no longer able to meet their nutritional 
requirements (Bishop & Reed, 2015).   Each method is associated with advantages and 
disadvantages.  Advantages of prophylactic PEG insertion include decreases in weight 
loss, malnutrition and dehydration related hospitalizations and less treatment 
interruptions.  Disadvantages to prophylactic tube placement include risks posed from 
surgery and non-use.  Reactive tube placement, however, often interrupts treatment.  
There is no consensus on whether prophylactic versus reactive placement of PEG tubes is 
preferable in Head and Neck cancer patients (Locher et al., 2011).   
A study by Kramer et al., (2014) looked to examine the outcomes of PEG tube 
placement timing (prophylactic vs. reactive) on weight loss, tube duration and disease 
control in patients with Head and Neck cancer.  The design was a historical cohort study 
with seventy-four patients identified for inclusion.  The population included those Head 
and Neck patient’s having received platinum-based chemotherapy and radiation as a 
primary modality and those patients with primary surgical resection having received 
adjuvant chemotherapy and radiation.  Percutaneous endoscopic gastric tube timing was 
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determined by patient and/or physician preference to be either prophylactic (before 
radiation began) or reactive (after radiation began) (Kramer et al., 2014).     
      Data was gathered, tabulated and analyzed to determine the effect of PEG tube 
placement timing on nutritional status-in which weight gain and survival were 
determined.  A second goal was to assess the effect of placement timing on PEG tube 
dependence and length of usage (Kramer et al., 2014). Student independent t-tests 
compared continuous variables and chi square and Fisher’s exact tests analyzed 
categorical variables (Kramer et al., 2014).  A hierarchical multiple regression analysis 
controlled confounders.  Kaplan-Meier analysis looked to determine if timing had an 
effect on PEG use.  Software then analyzed this data.   
      Researchers found that patients with prophylactic tube placement and advanced 
tumor stage had longer PEG tube duration.  Patients receiving reactive PEG tubes had 
them in place for fewer days than those placed prophylactically (227 versus 139 days, 
p<.01).  No difference in percentage weight loss was found at 2, 6 or 12 months.   Kramer 
et al., (2014) concluded that patients who receive reactive PEG tube placement may have 
them in for shorter durations of time without an increase in weight loss or worse 
outcomes.  Furthermore, the study showed that having a prophylactic PEG tube did not 
significantly improve enteral intake.  
 A retrospective study by Lang et al., (2020) evaluated the period of time between 
radiation initiation and PEG tube placement.  A secondary aim was to evaluate the course 
of weight change following PEG placement (Lang et al., 2020).  A retrospective chart 
review was conducted for Head and Neck cancer patients undergoing radiotherapy alone, 
or chemotherapy/radiation between January 2010 and August 2017 at the University 
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Hospital of Heidelberg.  All patients with Head and Neck cancer who underwent PEG 
tube placement before or during radiation were included in this study.  Patients receiving 
either concurrent chemotherapy or immunotherapy with radiation were also included.  
One hundred and eighty six patients were included in this study.   
 A retrospective analysis was conducted to determine initial weight and nutritional 
intake prior to radiation initiation and then followed throughout treatment until 
completion.  Demographic characteristics, body weight, body mass index (BMI), oral 
intake and patient-reported dysphagia and treatment related toxicities were examined 
(Lang et al., 2020).  Statistical analysis was conducted and results presented as means and 
percentages.  Kaplan-Meier estimates were calculated and Univariate analysis was 
conducted using logistic regression analysis.  For comparison between groups, chi-
squared and Student t-tests were performed.  IBM SPSS software analyzed the data. 
 This study demonstrated that patients with an initial low BMI (<18.5 kg/m2) and 
patients with pre-existing tumor-associated dysphagia were significantly more likely to 
receive earlier PEG placement.  Therefore, the examiners concluded that this subset of 
patients should be closely monitored for weight loss and decreased oral intake to 
determine the need for early PEG tube placement in an attempt to maintain adequate 
nutrition, improve treatment tolerance and reduce side effects (Lang et al., 2020).  
Twenty six patients had PEG tube insertion prior to radiation due to dysphagia and 
reluctant weight loss.  The remaining one hundred and sixty patients had PEG tube’s 
placed during radiation therapy.   
     In conclusion, this literature review found no consensus to support prophylactic 
PEG tube placement for improved nutritional outcomes within the Head and Neck cancer 
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population prior to radiation/chemotherapy.  Findings identify both benefits and harm.  
Additional research is needed to further this study topic and nutritional outcomes need 
specifying.  Additional study topics may include patient compliance, effects of alcohol 
intake and insurance coverage for enteral products as they apply to the outcomes for 
Head and Neck Cancer patients receiving concurrent chemotherapy and radiation. 
Surgery, radiation and chemotherapy are effective modalities used in combination 
or alone, to treat malignancies of the head and neck.  However, surgery for head and neck 
cancer can lead to facial disfigurement and functional disorders which can have a deep 
impact on social interactions and emotional wellbeing.  Body image disturbance, anxiety 
and dysfunctional coping are psychological consequences which can occur from 
disfiguring cancer treatment and PEG tube placement.  Using Lazarus and Folkman’s 
Theory of Stress, Adaptation and Coping, the emotional reactions to stress and relevant 















Lazarus and Folkman’s Theory of Stress, Adaptation and Coping evolved from 
Richard Lazarus’ 1966 Appraisal Theory of Stress which is borrowed from the social 
sciences.  It is considered a stress theory which both explains and describes the 
psychological response to stress.  It is intended to be a practice level theory with meta-
theoretical roots (Lazarus & Folkman, 1984 p. xi).  The concept of stress has historical 
underpinnings beginning in the 14th century to present time with theoretical works 
developed from various disciplines including biology, psychology, and social science 
backgrounds (Lazarus & Folkman, 1984, p.3).  
The basis of Lazarus’s original stress theory describes how a person copes 
psychologically with stressful situations.  Stress is considered to be a multitude of 
variables and processes.  The Theory of Stress, Adaptation and Coping, later developed 
by Lazarus and Folkman, used this approach as the basis for their theoretical framework.  
This framework aimed to examine the concept, specify antecedents, processes and 
outcomes relevant to the overarching concept of stress (Lazarus & Folkman 1984, p. 12).  
The theory’s intent was for practical use by a multitude of disciplines including nursing.  
According to Lazarus and Folkman, there are two major factors which precede 
stress.  These factors are called antecedents.  The first antecedent is the person-
environment relationship which includes values, beliefs, and social support among other 
factors.  The second antecedent is appraisal which is divided into three cognitive 
subtypes.  Primary appraisals refer to the judgments made about an event or stressor and 
secondary appraisals evaluate how the individual responds to them.  After additional 
information has been received, the third subtype, re-appraisal occurs.   
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Coping, per Lazarus, is the process in which threat is perceived and the appraisal 
is managed (McEwen & Wills 2011, p. 289).  The coping process is two-fold.  Problem-
focused coping changes the individual’s relationship with their environment whereas 
emotional coping changes the situations meaning.  The theory can be critiqued for not 
applying categories that are mutually exclusive and fully exhaustive (Andersen & Jarden, 
2012 p. 26).  Re-appraisal and adaptation are results of successful coping.  According to 
Lazarus and Folkman, adaptation affects health, psychological well-being and social 
functioning interdependently.   
Coping theory is becoming increasingly relevant with the rising prevalence of 
chronic diseases including cancer.  The theory is particularly useful to oncology nurses 
working with head and neck cancer patients who may not experience symptom relief.  
Educating patients about effective coping strategies could provide benefit and potentially 
improve quality of life for this patient population.  Lazarus and Folkman’s Theory of 
Stress, Adaptation and Coping has been utilized extensively in research as it relates to 
head and neck cancer patients and coping.   
A study by Andersen and Jarden (2012) explored how head and neck cancer 
patient’s coped with radiation and associated side effects.  The qualitative study applied 
Lazarus and Folkman’s theory of coping to the final stage of the study’s research 
analysis.  Nine patients were eligible for study but only five were participants.  Semi-
structured interviews were completed on this convenience sample.   
General meaning was extrapolated from the interviews and themes were 
developed.  The Theory of Stress, Adaptation and Coping was applied to the findings 
through further analysis to bring the main themes to a conceptual level (Andersen & 
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Jarden, 2012, p. 26).  The research question, “Which coping strategies do the patients 
apply?” was answered in five main themes:  Flying away, Recruiting help, Finding my 
place, Cognitive Control and Coping.  All main themes identified coping strategies which 
were action oriented and improved quality of life when controlled by the patient. 
 Hulbert-Williams et al., (2012), also explored Lazarus and Folkman’s Theory of 
Stress, Adaptation and Coping in full.  Their aim was to investigate the validity of the 
prescribed cognition-emotion relationships as outlined by Lazarus, using improved 
methodological and statistical approaches.  Their sample included 160 cancer patients 
diagnosed with curative intent in which a diagnosis of psychosocial adjustment to cancer 
was made.   
A repeat measures design was used.  A self-reported questionnaire was completed 
soon after diagnosis, and at three and six month follow ups.  Data on appraisals, core-
relational themes and emotions were collected. Twelve core relational themes were 
identified and the three most common included self-blame, loss/helplessness and threat.   
Data collected in the study supported the structure of Lazarus and Folkman’s 
theory and identified its sound empirical base.  It was suggested by Hulbert-Williams et 
al. (2012) that larger scale research is needed using more complex statistical testing.  The 
above research studies are examples that Lazarus and Folkman’s theory continues to be 
relevant to the nursing profession.  
The above research examples support the testability and usefulness of Lazarus 
and Folkman’s Theory of Stress, Adaptation and Coping.  The theory has been applied 
extensively in nursing research and has been shown useful in practice.  Emotional 
wellbeing and effective coping is desired in all patient populations.  Proper assessment of 
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stress and coping will provide holistic care and provide proper referral for psycho-social, 
supportive or palliative interventions.  The application of stress theory to nursing practice 
is important.  It provides a framework for nurses to assess the effects of stress and the 
coping processes that patients use.  Identifying coping resources and support structures 
and educating patients about them may facilitate effective coping strategies.  Research 
nurses, administrators, educators and bed-side nurses alike can incorporate Lazarus and 























 The purpose of this proposed research was to describe nutritional outcomes of 
weight, body mass index, total protein and albumin and their relative change in the Head 
and Neck cancer population receiving concurrent chemotherapy/radiation in those 
patients with prophylactic percutaneous gastrostomy (PEG) tubes versus those without.   
Design 
 The proposed study is a descriptive retrospective chart review of all Head and 
Neck cancer patients treated with concurrent chemotherapy/radiation between January 1, 
2000 and December 31, 2019 who are eligible.  Patient’s electronic medical record data 
meeting the criteria will be collected and analyzed.   
Sample and Site 
 A convenience sample of all adult patients diagnosed with Head and Neck cancer 
was obtained.  Inclusion criteria for this study consisted of male and female patients with 
Head and Neck cancer who received chemotherapy and radiation at Sturdy Memorial 
Hospital and Brigham and Women’s/Sturdy Memorial Radiation Oncology Center.  All 
patients with Head and Neck cancer originating from sites which include the 
nasopharynx, oropharynx, oral cavity and hypopharynx, regardless of HPV status were 
included.  This study also included adult patients who were treated with curative intent 
for stages I-IV cancer with squamous cell pathology and had PEG tubes placed either 
before (prophylactically) or during (reactively) chemotherapy/radiation administration.  
Exclusion criteria omitted patients with Stage 0 Head and Neck cancer, patients with 
recurrent or metastatic disease and those who did not complete chemotherapy/radiation.  
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Patients with histological Head and Neck cancer pathology types other than squamous 
cell and patients treated with palliative intent were be excluded.   
Procedures                                            
 Institutional Review Board approval was obtained at Sturdy Memorial Hospital 
and Rhode Island College prior to the study.  Other ethical considerations included 
research ethics and compliancy training (CITI program), HIPPA, data protection and 
patient confidentiality. 
Measurement 
 The data collection plan identified for this retrospective chart review included 
recording quantitative data found within the hospital’s electronic medical record systems 
which included Meditech, Centrictiy, Intellidose, Intellidose TXM and/or Cerner.  Data 
collection included the Eastern Cooperative Oncology Group performance status, ICD-10 
code, tissue of origin, cancer stage, treatment protocol, PEG tube placement and timing 
of tube placement.  Weight, body mass index, total protein and albumin levels were 
captured at baseline, prior to beginning cancer treatment and again upon completion of 
treatment.  The data was collected and analyzed by one evaluator.  A Microsoft Excel 
spread sheet was used for data organization, management, and storage. 
Dissemination 
 The proposed research will be disseminated as a major paper on the Rhode Island 
College Digital commons website.  A poster presentation will be completed.  The poster 
will also be presented at the Sturdy Memorial Hospital quality fair.  Professional 
publication will be considered.   




A total of 45 medical records were reviewed to obtain a cohort of 28 patients with 
Head and Neck Cancer who received concurrent chemotherapy and radiation and who 
had percutaneous endoscopic gastrostomy tubes placed.  Group A included 27 subjects 
(n=27) who had a percutaneous endoscopic gastrostomy tube placed prior to the initiation 
of concurrent chemotherapy and radiation and Group B included 1 subject (n=1) who had 
a percutaneous endoscopic gastrostomy tube placed after chemotherapy and radiation was 
initiated.  Data collected for both Group A and Group B included weight, body mass 
index, total protein, and albumin levels.  The mean, median and range were computed for 
all categories of data collected and then compared between the two groups, then at two 
catch points, prior to and upon completion of concurrent chemotherapy and radiation.  
Table 1 summarizes the data collected in both Group A and Group B of patients prior to 
the start of concurrent chemotherapy and radiation.  Table 2 summarizes the data in both 
groups of patients upon completion of concurrent chemotherapy and radiation. 
Table 1 Comparison between Group A and Group B Pre-treatment 
 Weight Body Mass Index  TP Albumin 
Group A   
Prophylactic PEG tube 
placement pre-treatment         
Mean 179.5 27.2 7.2 3.4 
Median 136.5 22.9 7.1 3.6 
Range 96-235 15.4-49.9 5.8-8.1 2.5-4.2 
Group B  
Reactive PEG tube 
placement pre-treatment         
Mean 248 34.6 6.2 4 
Median          





 Table 2 Comparison between Group A and Group B Post-treatment 
 Weight Body Mass Index  TP Albumin 
Group A   
Prophylactic PEG tube 
placement post-
treatment         
Mean 169.6 25.7 6.8 3.3 
Median 131.5 22.1 6.7 3.3 
Range 93-340 14.8-47.4 5.7-8.6 2.4-4.3 
Group B  
Reactive PEG tube 
placement post-
treatment         
Mean 230 32.1 6.1 3.7 
Median          
Range         
 
 Table 1 compares the weight, body mass index, total protein, and albumin scores 
for two groups of patients, those who had PEG tubes placed prophylactically (Group A) 
and those who had PEG tubes placed reactively (Group B) prior to concurrent 
chemotherapy and radiation beginning.  The weight range in Table 1 group A was 
between 89 and 358 pounds with the mean weight being 179.5 pounds.  The mean body 
mass index for group A was 27.2 with the range being between 15.4 and 49.9.  The mean 
total protein level was 7.2 with the range being between 6 and 9.1.  The mean albumin 
level was 3.4 with the range being between 2.5 and 4.  Group B contained only one 
patient (N=1).  Therefore, the measurements of weight, body mass index, total protein 
and albumin reflect both the value and mean of this small data set of one patient.  The 
patient’s in Group A who had prophylactic PEG tubes placed prior to treatment weighed 
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less, had lower body mass indexes and albumin levels but had higher total protein levels 
when compared to the one patient in Group B. 
 Table 2 compares the weight, body mass index, total protein, and albumin scores 
for two groups of patients, those who had PEG tubes placed prophylactically (Group A) 
and those who had PEG tubes placed reactively (Group B) upon completion of 
concurrent chemotherapy and radiation.  The weight range in Table 2 Group A was 
between 88 and 340 pounds with the mean weight being 169.6 pounds.  The mean body 
mass index for Group A was 25.7 with the range being 14.8 and 47.4.  The mean total 
protein level was 6.8 with the range being between 5.7 and 8.6.  The range for albumin 
was 2.4 and 4.1 with the mean being 3.3.  Group B consisted of one patient (N=1), 
therefore, the measurements of weight, body mass index, total protein, and albumin, 
reflect both the individual value and the mean of this one patient data set.   
Table 3 Comparison of average change percentages between Group A and Group B at 







change %Albumin change 
Group A 
Prophylactic 
Peg Tubes -5.48% -5.35% -4.4 -1.88 
Group B 
Reactive Peg 
Tubes -7.26 -7.23 -1.61 -7.5 
 
 Table 3 compares the average percent change in weight, BMI, total protein, and 
albumin levels for patients with prophylactic PEG tubes (Group A) versus patients who 
had PEG tubes placed reactively (Group B) at the completion of treatment.  Patients with 
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prophylactic PEG tubes (Group A) had a 5.48% average decrease in weight upon 
completion of treatment whereas the one patient with a reactive PEG tube (Group B), had 
a 7.26% decrease in weight.  Average decrease in body mass index for patients upon 
treatment completion was 5.35% in Group A and 7.23% for the one patient in Group B.  
The average percentage of decrease in total protein levels were greater in Group B (-
1.61%) than in Group A (-4.4 %).  Albumin percentage decrease was also greater in 
Group B (-7.5% versus -1.88%).   This data suggests a greater percentage of weight loss, 
decreased body mass index and albumin with less of a percentage decrease in total 
protein for patients with reactive PEG tubes placed when measured upon completion of 










Summary and Conclusions 
 Approximately 35% to 60% of all patients with Head and Neck cancers are 
malnourished at the time of their diagnosis because of tumor burden and obstruction of 
intake or the anorexia and cachexia associated with their cancer (Alshadwi et al., 2013).  
When administration of intensive multimodal treatments is concurrent, severe, and often 
debilitating effects can compromise the patient’s ability to maintain adequate nutrition 
and hydration (Orphanidou et al., 2011).  Patients unable to maintain adequate oral intake 
have greater rates of weight loss, hospitalization and forced treatment breaks (Bishop & 
Reed, 2015).  In Head and Neck cancer patients undergoing definitive chemotherapy and 
radiation, there are two approaches to percutaneous endoscopic gastric tube feeding-first 
to insert the tubes prior to treatment in anticipation of inadequate intake or second to 
insert a tube when patients are no longer able to meet their nutritional requirements 
(Bishop & Reed, 2015).   There is no consensus on the optimal timing of PEG tube 
placement for patients undergoing therapy for Head and Neck cancer (Kramer et al., 
2014).   
The purpose of this study was to describe nutritional outcomes in the Head and 
Neck cancer population receiving concurrent chemotherapy and radiation in those 
patients with prophylactic endoscopic gastric tubes versus those with reactive tube 
placements.  This study was guided by Lazarus and Folkman’s Theory of Stress, 
Adaptation and Coping.  A retrospective chart review was conducted, and forty-five 
charts were reviewed.  Twenty- eight patients met the studies inclusion criteria and were 
subsequently separated into two groups.  Group A was Head and Neck cancer patients 
with prophylactic endoscopic gastric tubes and Group B was Head and Neck cancer 
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patients with reactive prophylactic endoscopic gastric tubes.  A data collection tool was 
developed based on literature and clinical experience which included patient weight, 
body mass index, total protein, and albumin levels.  Weight, body mass index, total 
protein and albumin levels were captured at baseline, prior to beginning cancer treatment 
and again upon completion of treatment then compared between the two groups.  The 
average change percentages of weight, body mass index, total protein and albumin were 
also compared between Group A and Group B.  The final sample size of Group A 
included twenty-seven patients (n=27) and Group B had a final sample size of 1 patient 
(n=1).   
Table 1 compared weight, body mass index, total protein and albumin levels 
between patients who had percutaneous endoscopic gastric tubes placed prophylactically 
and reactively prior to beginning concurrent chemotherapy and radiation.  The mean 
weight, body mass index and albumin were lower in patients with prophylactic tubes 
(Group A) when compared to those with reactive tubes placed (Group B) prior to starting 
cancer treatment.  Lower weight, body mass index and albumin levels in Group A 
indicates that those patients having feeding tubes placed prophylactically may have had 
significant pre-treatment weight loss, significant airway obstruction or severe dysphagia.   
Table 2 compared the same data sets between patients who had percutaneous 
endoscopic gastric tubes placed prophylactically versus reactively at the completion of 
their cancer treatment.  Again, average weight, body mass index and albumin levels were 
found to be lower in patients with prophylactic tubes (Group A) when compared to those 
with reactive tubes placed (Group B).  This finding suggests that despite early 
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intervention with gastric tube placement, patients continued to lose weight and show 
signs of nutritional impairment upon completion of cancer treatment.   
Table 3 compared weight loss, body mass index, total protein, and albumin 
percent changes in patients with prophylactic percutaneous gastric tubes (Group A) 
against those with reactive percutaneous gastric tubes (Group B) at the completion of 
treatment.  Although both groups had decreases in weight, body mass index, total protein 
and albumin from their pre-treatment measures, patients with reactive tubes placed had a 
greater percentage of decline in all touch points except total protein.  This data identified 
that prophylactic timing of tube placement did not prevent malnutrition and may not have 
a significant impact on patients overall nutritional outcomes.     
This study had many limitations.  This research was limited by a small sample 
size, in part, due to the low incidence of Head and Neck cancers which are relatively rare 
and account for less than five percent of all cancer cases diagnosed in the United States 
yearly.  The study also took place in a community hospital setting, that lacks a designated 
Head and Neck cancer clinic, which may have further attributed to the small sample size.  
Other study limitations included the exclusion criteria.  Nine patients had no 
percutaneous gastric tubes placed, one patient never used their tube for artificial nutrition, 
three patients did not complete their planned treatment protocols, and four medical 
records had incomplete data sets.  Therefore, these seventeen patients were excluded 
from the study.  The most significant limitation was the small sample size of patients with 
reactive percutaneous endoscopic gastric tubes (N=1).        
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It was noted in the patient’s medical records that of the twenty-seven patients who 
had gastric tubes placed prophylactically, only nine patients started artificial nutrition 
prior to their cancer treatment.  These nine patients had an average of twenty-six days of 
artificial nutrition prior to starting their cancer treatments.  The remaining eighteen 
patients started using artificial nutrition on an average of nineteen days after concurrent 
chemotherapy and radiation started despite having had prophylactic percutaneous 
endoscopic gastric tubes placed prior to their treatment’s initiation.  Factors that may 
have influenced artificial nutrition start time were personal preference, insurance 
approval for artificial nutrition and gastric tube complications.  Other factors for delaying 
artificial nutrition could not be discerned.  The one patient with a reactive percutaneous 
endoscopic gastric tube had it placed eighteen days after treatment began and artificial 
nutrition was started the same day.  It is important to recognize that timing of tube 
placement does not always coincide with timing of artificial nutrition commencing.  
There is currently no consensus in the literature to guide the timing of tube placement.  
Understanding the reasons that artificial nutrition is not started at time of tube placement 
could glean pertinent information, identify barriers to care and help guide practice.   
In summary, this research study described the nutritional outcomes in Head and 
Neck cancer patients receiving concurrent chemotherapy and radiation who had 
percutaneous endoscopic gastric tubes placed either prophylactically or reactively.  The 
study results identified that all patients, despite timing of tube placement, lost weight and 
showed signs of worsening nutritional status.  This was evidenced by decreases in body 
mass index, total protein, and albumin in both patient groups.  Identifying and eliminating 
factors associated with delayed enteral nutrition may hasten tube to feed time and 
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enhance patients overall nutritional status.  More research is needed to assist clinicians in 
choosing high risk patients who will likely benefit from gastric tube placement and low 
risk patients who can forgo tube placement all together.  Next, recommendations and 




Recommendations and Implications for Advanced Nursing Practice 
The advanced practice registered nurse (APRN) plays a vital role in accurately 
assessing the Head and Neck cancer patient prior to receiving concurrent chemotherapy 
and radiation to determine if prophylactic feeding tube placement is indicated.  A risk 
assessment tool can be developed by the APRN using NCCN recommendations for 
prophylactic percutaneous endoscopic gastric tube placement.  For those patients who do 
not require prophylactic PEG tube placement, the APRN can work collaboratively with 
the Registered Dietician (RD) to monitor patient’s nutritional status using validated 
malnutrition screening tools.  Tracking patient’s weight, body mass index, total protein, 
and albumin changes in addition to malnutrition screenings can be useful to identify 
patients who may require reactive PEG tube placements.  The APRN helps to coordinate 
care and has appropriate referral processes in place to expedite surgical placement of 
these tubes for patients with Head and Neck cancer. 
Another innovative APRN strategy to enhance Head and Neck cancer patients 
overall nutritional status is in the development of a pre-habilitation clinic.  An 
interdisciplinary approach to the care of the Head and Neck cancer patient would provide 
advanced practice nurse assessment and medical management prior to cancer treatment 
initiation.  The multidisciplinary team of registered dieticians, physical therapists, speech 
and language pathologists, social workers, case managers and chaplains could facilitate 
patient centered care, improve patient satisfaction, and enhance overall outcomes.  
Patients and families would be educated early to prepare patients for cancer treatment and 
allow for early interventions to enhance patients overall nutritional status.   
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A follow up clinic led by advanced practice nurses can allow for more frequent 
outpatient visits and more intense symptom management once active treatment has 
started.  Frequent follow up appointments for patients in active treatment may decrease 
emergency room visits, prevent admissions, enhance nutritional outcomes, and improve 
quality of life.  The APRN plays a pivotal role in improving health care value and 
potentially decreasing the burden on the healthcare system by avoiding inappropriate use 
of healthcare resources by preventing unnecessary emergency room visits and avoiding 
admissions.   
This study identified that despite the timing of percutaneous endoscopic gastric 
tube placement, all patients lost weight and had worse nutritional outcomes upon 
treatment completion.  In addition, the timing of PEG tube placement did not always 
coincide with artificial nutrition initiation.  Sixty-seven percent of patients with 
prophylactic PEG tubes began using artificial nutrition an average of nineteen days after 
the cancer treatment began.  Additional research is needed to determine the factors 
associated with delays in time to tube feed so that barriers to early nutritional support can 
be identified and mitigated.  Excellent nutrition management is essential to improve the 
Head and Neck cancer patient’s overall wellbeing and minimize weight loss.   
In conclusion, there is no consensus in the literature to guide appropriate timing 
for percutaneous endoscopic tube placement in the Head and Neck cancer patient treated 
with combination chemotherapy and radiation.  Patient and provider preference continues 
to be the mainstay for decision making.  Randomized studies are needed in multicenter, 
large cancer intensive sites with a high volume of Head and Neck cancer patients to 
determine best timing of tube placement with the desired goal of achieving optimal 
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nutritional outcomes.  APRN’s must participate in and utilize current research to change 
the standard of care in this complex patient population. Evidence-based practice and a 
multi-disciplinary innovative approach may improve patient care and enhance nutritional 
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